JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB59047

FITC Anti-DR4 antibody [DR-4-02]

Be the first to review this product! Submit a review

|

(4 Publications)

Mouse Monoclonal DR4 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Transfected cell line - Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within Human TNFRSF10A.

View Alternative Names

CD261, APO2, DR4, TRAILR1, TNFRSF10A, Tumor necrosis factor receptor superfamily member 10A, Death receptor 4, TNF-related apoptosis-inducing ligand receptor 1, TRAIL receptor 1, TRAIL-R1

1 Images
Flow Cytometry - FITC Anti-DR4 antibody [DR-4-02] (AB59047)
  • Flow Cyt

Supplier Data

Flow Cytometry - FITC Anti-DR4 antibody [DR-4-02] (AB59047)

Anti-Hu CD261 FITC antibody (concentration in sample 3 μg/ml, red-filled histogram) binds specifically to CD261 on surface of CD261 transfected HEK-293 cells (upper panel), but not to surface of non-transfected HEK-293 cells (lower panel). Level of non-specific binding was assessed using Mouse IgG1 isotype control FITC antibody under same conditions (concentration in sample 3 μg/ml, black-dashed histogram).

  • Carrier free

    Anti-DR4 antibody [DR-4-02] - Low endotoxin, Azide free

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

DR-4-02

Isotype

IgG1

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Recombinant Fragment Protein within Human TNFRSF10A. The exact immunogen used to generate this antibody is proprietary information.

O00220

Specificity

The antibody recognizes TRAIL R1 (DR4), a human death receptor 4 (468 amino acids) expressed in most human tissues (spleen, peripheral blood leucocytes, thymus) and in a variety of tumour derived cell lines.

style
left-column

Alternative Products

Primary Antibodies

AB65810

PE Anti-DR4 antibody [DR-4-02]

Flow Cytometry - PE Anti-DR4 antibody [DR-4-02] (AB65810)

  • 0
  • 0
Primary Antibodies

AB192337

APC Anti-DR4 antibody [DR-4-02]

Flow Cytometry - APC Anti-DR4 antibody [DR-4-02] (AB192337)

  • 0
  • 0
Primary Antibodies

AB216662

Anti-DR4 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-DR4 antibody (AB216662)

  • 0
  • 0

Complementary Products

Assay Kits

AB282881

Human DR4 ELISA Kit

Recombinant|SimpleStep

Sandwich ELISA - Human DR4 ELISA Kit (AB282881)

  • 0
  • 0
Primary Antibodies

AB53319

FITC Anti-DR5 antibody [DR5-01-1]

Flow Cytometry - FITC Anti-DR5 antibody [DR5-01-1] (AB53319)

  • 0
  • 0
Primary Antibodies

AB8421

Anti-FLIP antibody

Immunocytochemistry/ Immunofluorescence - Anti-FLIP antibody (AB8421)

  • 4
  • 11
Primary Antibodies

AB32397

Anti-Caspase-8 antibody [E7]

20ul selling size|KO Validated|RabMAb|Recombinant

Western blot - Anti-Caspase-8 antibody [E7] (AB32397)

  • 3
  • 2
Primary Antibodies

AB133504

Anti-Cytochrome C antibody [EPR1327]

RabMAb|Recombinant|20ul selling size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytochrome C antibody [EPR1327] (AB133504)

  • 5
  • 2
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" }, "Transfected cell line - Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "3-5 µg/mL", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/fitc-mouse-igg1-b11-6-isotype-control-ab91356'>ab91356</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" } } }
style
left-column

Product details

Do not use after expiration date stamped on vial label. Short term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.

Soluble antibody blocks DR4 receptor against TRAIL induced apoptosis. Plastic immobilized antibody induces apoptosis in sensitive cells.

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Size-exclusion chromatography
Purification notes
The antibody was >95% pure prior to conjugation as determined from SDS-PAGE (by protein A affinity chromatography).
Storage buffer
pH: 7.4 Preservative: 0.097% Sodium azide Constituents: 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

DR4 also known as TRAIL-R1 is a receptor with a molecular weight of approximately 60 kDa. It is part of the tumor necrosis factor receptor (TNFR) superfamily. DR4 is widely expressed in various types of tissues such as the liver spleen thymus and peripheral blood leukocytes. It functions mechanically by binding to its ligand TNF-related apoptosis-inducing ligand (TRAIL) which initiates signaling cascades that lead to apoptosis or programmed cell death.
Biological function summary

The death receptor 4 plays an important role in mediating cell apoptosis. Upon ligand binding DR4 interacts with the adapter molecule FADD (FAS-associated protein with death domain) facilitating the formation of the death-inducing signaling complex (DISC). This complex recruits and activates caspase-8 which eventually leads to the activation of the downstream effector caspases driving the cell towards apoptosis. DR4 operates as a significant component of the extrinsic pathway of apoptosis a process important for maintaining cellular homeostasis and eliminating harmful cells.

Pathways

DR4 functions critically within the extrinsic apoptotic pathway. This pathway involves other death receptors such as DR5 which also binds TRAIL similarly leading to apoptosis through DISC formation and caspase activation. The extrinsic pathway interconnects with the intrinsic pathway via the mitochondria with proteins like Bid acting as a bridge between them. The engagement of these pathways highlights DR4's importance in regulatory mechanisms of cell death tightly controlling cellular proliferation and survival.

DR4 plays a significant role in cancer and autoimmune diseases. Alterations in DR4 expression or function can lead to evasion of apoptosis by cancer cells contributing to tumor progression. The defective apoptotic signaling via DR4 is also linked to autoimmune disorders where insufficient apoptosis may allow for the survival of autoreactive immune cells. In both scenarios DR4's involvement usually associates with its counterpart DR5 as they share similar ligand-binding properties and signal transduction mechanisms in diseased states.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed : 26457518, PubMed : 38532423). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis (PubMed : 19090789). Promotes the activation of NF-kappa-B (PubMed : 9430227).
See full target information TNFRSF10A
style
left-column

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Methods in molecular biology (Clifton, N.J.) 1866:61-73 PubMed30725408

2019

Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Strekalova,Dmitry Malin,Harisha Rajanala,Vincent L Cryns

Clinical cancer research : an official journal of the American Association for Cancer Research 24:2452-2463 PubMed29363524

2018

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.

Applications

Unspecified application

Species

Unspecified reactive species

Luke Piggott,Andreia Silva,Timothy Robinson,Angelica Santiago-Gómez,Bruno M Simões,Michael Becker,Iduna Fichtner,Ladislav Andera,Philippa Young,Christine Morris,Peter Barrett-Lee,Fouad Alchami,Marco Piva,Maria dM Vivanco,Robert B Clarke,Julia Gee,Richard Clarkson

PloS one 7:e49219 PubMed23145127

2012

Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.

Applications

Flow Cyt

Species

Human

Irina Nesterenko,Simone Wanningen,Tugba Bagci-Onder,Maarten Anderegg,Khalid Shah

Anti-cancer drugs 21:10-24 PubMed19823077

2009

Scatter factor protects tumor cells against apoptosis caused by TRAIL.

Applications

IP

Species

Unspecified reactive species

Saijun Fan,Qinghui Meng,John J Laterra,Eliot M Rosen
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com